Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02008227 · FLOW

Participant flow

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy · Source last updated 2019-12-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Docetaxel 75 milligrams per square meter (mg/m\^2) was administered intravenously (IV) on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.
    id
    FG000
    title
    Docetaxel
  2. description
    Atezolizumab 1200 milligrams (mg) was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.
    id
    FG001
    title
    Atezolizumab
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        7
      2. group Id
        FG001
        num Subjects
        9
      type
      Lost to Follow-up
    2. reasons
      1. group Id
        FG000
        num Subjects
        494
      2. group Id
        FG001
        num Subjects
        485
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        67
      2. group Id
        FG001
        num Subjects
        36
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        44
      2. group Id
        FG001
        num Subjects
        83
      type
      Study Terminated By Sponsor
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        612
      2. group Id
        FG001
        num Subjects
        613
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        579
      2. group Id
        FG001
        num Subjects
        608
      type
      Treated
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        612
      2. group Id
        FG001
        num Subjects
        613
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Twelve hundred and twenty-five participants were randomized in the study and were considered the Secondary Population (SP), out of which first 850 randomized participants were considered the Primary Population (PP).
Complete source fields
groups
  1. description
    Docetaxel 75 milligrams per square meter (mg/m\^2) was administered intravenously (IV) on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.
    id
    FG000
    title
    Docetaxel
  2. description
    Atezolizumab 1200 milligrams (mg) was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.
    id
    FG001
    title
    Atezolizumab
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        7
      2. group Id
        FG001
        num Subjects
        9
      type
      Lost to Follow-up
    2. reasons
      1. group Id
        FG000
        num Subjects
        494
      2. group Id
        FG001
        num Subjects
        485
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        67
      2. group Id
        FG001
        num Subjects
        36
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        44
      2. group Id
        FG001
        num Subjects
        83
      type
      Study Terminated By Sponsor
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        612
      2. group Id
        FG001
        num Subjects
        613
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        579
      2. group Id
        FG001
        num Subjects
        608
      type
      Treated
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        612
      2. group Id
        FG001
        num Subjects
        613
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Twelve hundred and twenty-five participants were randomized in the study and were considered the Secondary Population (SP), out of which first 850 randomized participants were considered the Primary Population (PP).

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice